4D Molecular Therapeutics (FDMT) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed MiMedx Group (MDXG) over the past year, gaining 51.3% versus a loss of 36.5%. Over five years, MDXG leads with a -31.8% price change compared with -53.9% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($695.5 million vs $672.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | MDXG |
|---|---|---|
| Share price | $12.59 | $4.61 |
| Market cap | $695.52M | $672.76M |
| 1-day change | +0.24% | -0.22% |
| YTD return | +67.87% | -31.91% |
| 1-year return | +51.32% | -36.50% |
| 5-year return | -53.92% | -31.80% |
| P/E ratio (TTM) | — | 115.25 |
| Forward P/E | — | 23.05 |
| EPS (TTM) | $-2.63 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $7.97 |
| 52-week low | $6.96 | $3.03 |
| Distance from 52-week high | -25.63% | -42.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.11% | +60.52% |
| Average volume | 924.05K | 1.23M |
| Shares outstanding | 55.24M | 145.93M |
| Employees | 196 | 808 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed MDXG by 87.8 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Healthcare · Biotechnology · 196 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Healthcare · Biotechnology · 808 employees
FDMT vs MDXG FAQ
Which is bigger, 4D Molecular Therapeutics or MiMedx Group?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $695.52M compared with $672.76M for MiMedx Group (MDXG).
Which stock has performed better over the past year, FDMT or MDXG?
FDMT returned +51.32% over the past 12 months, compared with -36.50% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and MiMedx Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.